Delving into the Latest Updates on NovaCell Technology, Inc. with Synapse

Overview

Basic Info

Introduction

NovaCell Technology is a company that specializes in the production of biomaterials through the use of peptide libraries and proteome profiling technology. By selecting potential peptide and biomarker candidates from a range of model systems, the company is able to create biopharmaceuticals and biomaterials using advanced technologies in proteomics and peptide libraries.

Tags

Digestive System Disorders

Skin and Musculoskeletal Diseases

Neoplasms

Antibody

Synthetic peptide

Recombinant polypeptide

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Endocrinology and Metabolic Disease	2
Infectious Diseases	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Antibody	4
Synthetic peptide	2
Recombinant polypeptide	1

Top 5 Target	Count

FPR1 x FPR2	1
ECM1(extracellular matrix protein 1)	1
GPCR(G-protein coupled receptor)	1
KRT19(keratin 19)	1
laminin	1

Pleurotus eryngii var. ferulae (PEF) is traditionally used in the prevention and treatment of lifestyle-related diseases. In this study, we investigated the ability of PEF extract to prevent obesity and metabolic diseases and explored the underlying mechanism. Mice were fed a high-fat diet (HFD) containing PEF extract for 12 weeks, and their body weight, adipose tissue and liver weights, and lipid profiles and blood glucose levels, were monitored. Fecal triglyceride (TG) levels were also measured and olive oil-loading tests were performed. Furthermore, the effect of PEF extract on pancreatic lipase (PL) activity was examined in vitro. Treatment with PEF extract for 12 weeks resulted in a significant decrease in the HFD-induced increases in body weight, white adipose tissue weight, liver weights, and lipid profiles, and improved glucose tolerance and insulin sensitivity. To assess the mechanism underlying the effect of PEF extract on obesity and diabetes, we investigated its role in inhibiting lipid absorption. Consumption of an HFD containing PEF extract significantly increased the TG level in feces compared with the controls, suggesting inhibition of TG absorption in the digestive tract. Furthermore, PEF extract suppressed the increase in serum TG levels resulting from oral administration of a lipid emulsion to mice, confirming inhibition of TG absorption. Moreover, PEF extract inhibited PL activity in vitro. Our combined results indicate that the anti-obesity and antidiabetic effect of PEF extract in mice fed an HFD may be caused by inhibition of lipid absorption as a result of reduced PL activity.

01 Aug 2018·Experimental & Molecular MedicineQ2 · MEDICINE

Mechanisms regulating intestinal barrier integrity and its pathological implications

Q2 · MEDICINE

ReviewOA

Author: Ghim, Jaewang ; Ryu, Sung Ho ; Chelakkot, Chaithanya

AbstractThe gastrointestinal tract is a specialized organ in which dynamic interactions between host cells and the complex environment occur in addition to food digestion. Together with the chemical barrier of the mucosal layer and the cellular immune system, the epithelial cell layer performs a pivotal role as the first physical barrier against external factors and maintains a symbiotic relationship with commensal bacteria. The tight junction proteins, including occludin, claudins, and zonula occludens, are crucial for the maintenance of epithelial barrier integrity. To allow the transport of essential molecules and restrict harmful substances, the intracellular signaling transduction system and a number of extracellular stimuli such as cytokines, small GTPases, and post-translational modifications dynamically modulate the tight junction protein complexes. An imbalance in these regulations leads to compromised barrier integrity and is linked with pathological conditions. Despite the obscurity of the causal relationship, the loss of barrier integrity is considered to contribute to inflammatory bowel disease, obesity, and metabolic disorders. The elucidation of the role of diseases in barrier integrity and the underlying regulatory mechanisms have improved our understanding of the intestinal barrier to allow the development of novel and potent therapeutic approaches.

01 Feb 2018·Experimental & Molecular MedicineQ2 · MEDICINE

Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions

Q2 · MEDICINE

ArticleOA

Author: Park, Hae-Sim ; Ryu, Sung H ; Choi, Youngwoo ; Kim, Yoon-Keun ; Chelakkot, Chaithanya ; Gho, Yong S ; Ghim, Jaewang ; Jee, Young-Koo ; Kwon, Yonghoon ; Kim, Min-Seon ; Jeon, Jinseong ; Park, Hyun T ; Kim, Dae-Kyum

The gut microbiota has an important role in the gut barrier, inflammation and metabolic functions. Studies have identified a close association between the intestinal barrier and metabolic diseases, including obesity and type 2 diabetes (T2D). Recently, Akkermansia muciniphila has been reported as a beneficial bacterium that reduces gut barrier disruption and insulin resistance. Here we evaluated the role of A. muciniphila-derived extracellular vesicles (AmEVs) in the regulation of gut permeability. We found that there are more AmEVs in the fecal samples of healthy controls compared with those of patients with T2D. In addition, AmEV administration enhanced tight junction function, reduced body weight gain and improved glucose tolerance in high-fat diet (HFD)-induced diabetic mice. To test the direct effect of AmEVs on human epithelial cells, cultured Caco-2 cells were treated with these vesicles. AmEVs decreased the gut permeability of lipopolysaccharide-treated Caco-2 cells, whereas Escherichia coli-derived EVs had no significant effect. Interestingly, the expression of occludin was increased by AmEV treatment. Overall, these results imply that AmEVs may act as a functional moiety for controlling gut permeability and that the regulation of intestinal barrier integrity can improve metabolic functions in HFD-fed mice.

100 Deals associated with NovaCell Technology, Inc.

Login to view more data

100 Translational Medicine associated with NovaCell Technology, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

7

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NCP111 ( FPR1 x FPR2 )	Sepsis More	Preclinical
NCT-201 ( KRT19 )	Stomach Cancer More	Preclinical
NCT-202 ( ECM1 )	Stomach Cancer More	Preclinical
NCT-203	Colorectal Cancer More	Preclinical
NCT-204/205	Glioma More	Preclinical